Takeda Pharmaceutical Limited (TAK) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Suppliers, else..
 
Takeda Pharmaceutical Company Limited  (NYSE: TAK)
 

Takeda Pharmaceutical Limited Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TAK Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q2 MRQ) - 6.4 % 5.55 % 4.2 %
Q / Q Revenue Growth (Q2 MRQ) -73.77 % -6.29 % -4.39 % -3.92 %
Y / Y Revenue Growth (for 12 months ending Q2 TTM) - 7.93 % 6.04 % %
Sequential Revenue Growth (for 12 months ending Q2 TTM) 20.78 % 1.16 % 1.02 % 1.07 %
Revenue 5 Year Average Growth -0.13 % 7.52 % 8.67 % 13.63 %


TAK's Growth Comparisons in I. Quarter 2026




Takeda Pharmaceutical Limited reported top-line of $ 7.65 billions in the first quarter 2026, compare to $ 0 millions in the same quarter a year ago. Revenues in the Major Pharmaceutical Preparations industry grew by 6.4%, while the top-line in the Healthcare sector increased by 5.55%, and overall market improved by 4.2% from the first quarter 2025.

Top-line fell by -73.77% from the fourth quarter results. Comparing the annual growth, sales of -0.13% on average in last five years, to the S & P 500's, including only Businesses with the first quarter 2026 financial results, average yearly sales growth is 13.63%. Takeda Pharmaceutical Limited grew less than the market.

TAK Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Sales of pharmaceutical products
-
-
Out-licensing and service income
-
-
Total Gastroenterology
-
-
ENTYVIO
-
-
GATTEX REVESTIVE
-
-
TAKECAB VOCINTI
-
-
PANTOLOC CONTROLOC
-
-
DEXILANT
-
-
EOHILIA
-
-
Others
-
-
Total Rare Diseases
-
-
TAKHZYRO
-
-
ADVATE
-
-
ELAPRASE
-
-
REPLAGAL
-
-
ADYNOVATE ADYNOVI
-
-
VPRIV
-
-
LIVTENCITY
-
-
ADZYNMA
-
-
Total PDT
-
-
Immunoglobulin
-
-
Albumin
-
-
Total Oncology
-
-
ADCETRIS
-
-
LEUPLIN ENANTONE
-
-
NINLARO
-
-
ICLUSIG
-
-
FRUZAQLA
-
-
ALUNBRIG
-
-
Total Vaccines
-
-
QDENGA
-
-
Total Neuroscience
-
-
VYVANSE ELVANSE
-
-
TRINTELLIX
-
-
ADDERALL XR
-
-
Total Other
-
-
AZILVA
-
-
FOSRENOL
-
-
Japan
-
-
U S
-
-
Europe and Canada
-
-
Latin America
-
-
China
-
-
Asia excluding Japan China
-
-
Russia CIS
-
-
Other
-
-
Cencora Group Customer risk concentration net sales
-
-
McKesson Group Customer risk concentration net sales
-
-
Total
-
-


Growth Rates of TAK's Income in the first quarter 2026


TAK Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q2 MRQ) - 129.36 % 83.92 % 2.39 %
Sequential Operating Income Change (Q2 MRQ) - -4.34 % -6.07 % 12.67 %
Y / Y Operating Income Growth (Q2 TTM) 49.02 % 104.2 % 61.57 % 6.79 %
Sequential Operating Income Growth (Q2 TTM) 0 % 23.04 % 12.67 % 0.65 %
Operating Income 5 Year Avg. Change 19.48 % 14.12 % 10.27 % 18.8 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q2 MRQ) - 365.81 % 214.07 % 14.03 %
Sequential Income from Cont. Ops. Change (Q2 MRQ) 3.17 % - 126.08 % 0.54 %
Y / Y Income from Cont. Ops. Change (Q2 TTM) 41.89 % 166.24 % 190.62 % 13 %
Sequential Income from Cont. Ops. Change (Q2 TTM) 103.17 % 35.18 % 15.74 % 2.54 %
Income from Cont. Ops. 5 Year Avg. Change 11.75 % 14.58 % 8.91 % -28.64 %

TAK Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q2 MRQ) - 366.57 % 206.62 % 13.51 %
Q / Q Net Income Growth (Q2 MRQ) 3.17 % 15.03 % 23.15 % -0.08 %
Y / Y Net Income Change (Q2 TTM) 41.41 % 49.57 % 49.42 % 11.01 %
Sequential Net Income Change (Q2 TTM) 45.87 % 33.81 % 25.46 % 2.45 %
Net Income 5 Year Avg. Growth 11.75 % 14.16 % 9.09 % 23.95 %

TAK's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q2 MRQ) - 267.37 % 214.07 % 14.03 %
Sequential EPS from Cont. Ops. Change (Q2 MRQ) - - 126.08 % 0.54 %
Y / Y EPS from Cont. Ops. Change (Q2 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q2 TTM) - - - -23.98 %
EPS from Cont. Ops. 5 Year Avg. Growth 19.2 % -0.46 % 8.91 % -28.64 %



TAK EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q2 MRQ) - 267.96 % 206.62 % -28.64 %
Q / Q EPS Net Growth (Q2 MRQ) - 3.31 % 23.15 % -0.08 %
Y / Y EPS Net Change (for 12 months ending Q2 TTM) - - - 0.14 %
Sequential EPS Net Change (for 12 months ending Q2 TTM) - - - -23.99 %
EPS Net 5 Year Avg. Change 18.93 % 14.16 % 9.09 % 23.95 %



Takeda Pharmaceutical Limited reported bottom-line of $ 0.00 in the first quarter, compare to $ 0.00 in the same quarter a year ago. Major Pharmaceutical Preparations industry grew by 267.96%, while Healthcare sector increased by 206.62%, and overall market improved by 13.51%.

Bottom-line fell by -73.77% from the fourth quarter results. Comparing the annual growth, income per share of 18.93% on average in last five years, to the S & P 500's, including only Businesses with the first quarter 2026 earnings, average yearly income per share growth is 23.95%. Takeda Pharmaceutical Limited grew less than the market.

TAK Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q2 MRQ) -80.32 % -2.64 % 8.24 % -92.81 %
Sequential Free Cash Flow Change (Q2 MRQ) -80.32 % -56.37 % -67.33 % -98.71 %
Y / Y Free Cash Flow Change (Q2 TTM) -6.73 % 19.16 % 19.29 % 7.78 %
Sequential Free Cash Flow Change (Q2 TTM) -46.27 % 1.34 % -0.56 % -2.25 %
Free Cash Flow 5 Year Avg. Change 0.62 % 0.88 % 0.41 % 1.79 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q2 MRQ) - 439.38 % - -
Sequential Net Cash Flow Change (Q2 MRQ) - 167.97 % - -
Y / Y Net Cash Flow Change (Q2 TTM) - -58.85 % - -
Sequential Net Cash Flow Change (Q2 TTM) - -54.14 % - -
Net Cash Flow 5 Year Avg. Change - 29.88 % 6.46 % 1.07 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q2 MRQ) 6.59 % 7.32 % 0.89 % 18.29 %
Sequential Capital Expenditures Change (Q2 MRQ) 6.59 % -17.11 % -20.15 % -17.95 %
Y / Y Capital Expenditures Change (Q2 TTM) 326.31 % 8.53 % 6.34 % 39.53 %
Sequential Capital Expenditures Change (Q2 TTM) 1.57 % 4.86 % 1.83 % 5.69 %
Capital Expenditures 5 Year Avg. Change 1.81 % 7.88 % 8.63 % 14.2 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.